YOLFTbeta
Oncozenge AB

Oncozenge AB

ONCOZ · ST · Healthcare / Biotechnology

3.25SEK-0.00 (-0.15%)

Price History

Full chart

Market Stats

Previous Close3.25
Open3.30
Day Range3.13 – 3.30
52-Week Range3.10 – 8.70
Volume31.42K
Market Cap88.05M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.69
Dividend Yield0.00%
Beta1.30
50-Day Avg4.79
200-Day Avg5.91

About

OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Stian Kildal
  • Employees1
  • HeadquartersGustavslundsvägen 34, 5 tr, Bromma, Sweden, 167 51, Sweden
  • Websitehttps://oncozenge.com

Leadership

  • Mr. Stian KildalChief Executive Officer · b. 1976
  • Mr. Michael Owens B.A., B.S., B.S.B.AChief Financial Officer · b. 1956
  • Ida SparrfeldtChief Auditor · b. 1986
  • Ms. Tuulikki LindmarkHead of CMC in Phase 3 Sponsor Team
  • Dr. Marie-Louise Helena Fjallskog M.D., Ph.D.Chief Medical Officer · b. 1964
  • Ms. Linda NordHead of Regulatory Affairs

Financials

Income Statement

Currency: SEK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0003.00K1.00K2.66M
Growth (%)-----66.67%+266300.00%
Cost of Revenue000--7.50M
Gross Profit0003.00K1.00K-4.84M
Gross Margin---100.00%100.00%-181.68%
Operating Expense801.00K4.89M43.57M15.90M8.69M11.03M
Operating Income-801.00K-4.89M-43.57M-15.90M-8.69M-15.87M
Operating Margin----530066.67%-868500.00%-595.72%
EBITDA-801.00K-4.89M2.77M7.27M-8.69M-15.87M
EBITDA Margin---242200.00%-868500.00%-595.72%
Net Income-636.00K-3.89M-46.65M-15.90M-8.69M-15.94M
Net Income Margin----530066.67%-868800.00%-598.35%
R&D0216.00K37.64M7.39M1.72M11.03M
R&D as % of Total Revenue---246466.67%171900.00%414.04%
Interest Expense00004.00K169.00K
Interest Expense % of Total Revenue---0.00%400.00%6.34%

Balance Sheet

Currency: SEK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets38.30M85.23M36.89M20.34M11.43M15.34M
Total Liabilities9.01M4.90M2.92M1.70M1.48M15.92M
Total Equity29.28M80.32M33.97M18.64M9.95M-587.00K
Cash10.00M51.22M29.14M12.63M3.86M3.71M
Total Debt-----7.50M
Net Debt-10.00M-51.22M-29.14M-12.63M-3.86M3.79M

Cash Flow

Currency: SEK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.00K-4.77M-22.08M-17.08M-8.76M-13.06M
Investing Cash Flow-5.36M-5.36M-570.00K--
Financing Cash Flow10.00M51.34M-570.00K-12.91M
Capital Expenditure05.36M00013.06M
Free Cash Flow-1.00K-10.12M-22.08M-17.08M-8.76M-13.06M
FCF to OCF100.00%212.36%100.00%100.00%100.00%100.00%

Earnings

Report DateMay 18, 2021Jun 30, 2021Sep 30, 2021Feb 15, 2022May 17, 2022Aug 16, 2022Nov 15, 2022Feb 14, 2023May 16, 2023Aug 31, 2023Oct 31, 2023Feb 15, 2024May 21, 2024Aug 9, 2024Nov 18, 2024Feb 20, 2025May 15, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------
EPS Actual-0.09-0.09-0.06-0.09-3.08-0.24-0.27-0.39-0.35-0.38-0.36-0.27-0.20-0.18-0.15-0.210.00-0.19-0.23-0.65-0.45-0.34
Surprise----------------------
Timing---Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-----

Key Statistics & Ratios

Market Cap88.05M
Enterprise Value94.42M
Trailing P/E0.00
Forward P/E0.00
Price / Sales14.74
Price / Book8.94
EPS-1.69
Book Value0.698
Revenue (TTM)5.97M
Gross Profit (TTM)5.97M
EBITDA7.27M
Profit Margin0.00%
Operating Margin-91.25%
Return on Equity-231.25%
Return on Assets-76.19%
Shares Outstanding25.05M
Shares Float5.39M
Beta1.30
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%